metoclopramide has been researched along with Ovarian Neoplasms in 30 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the combined effect of granisetron and methylprednisolone against acute emesis induced by cytotoxic agents, we investigated the clinical response and the urinary excretion of 5-HIAA in 85 patients with ovarian cancer who received the same anticancer chemotherapeutic regimen in a prospective randomized trial." | 9.08 | Combination effect of granisetron and methylprednisolone for preventing emesis induced by cytotoxic agents. ( Cheng, X; Itamochi, H; Kigawa, J; Minagawa, Y; Okada, M; Terakawa, N, 1997) |
| "To determine the severity of emesis caused by ultra-high-dose cisplatin-carboplatin chemotherapy and to compare the antiemetic efficacy of an ondansetron regimen and a metoclopramide regimen." | 9.07 | Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy. ( Fanning, J; Hilgers, RD, 1994) |
| " The syndrome was associated with metoclopramide antiemetic therapy given for post-operative nausea and vomiting." | 7.68 | Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy. ( Bakri, YN; Kawi, Z; Khan, R; Subhi, J, 1992) |
| "In prospective alternative crossover test, we confirmed significant superiority of a three-drug combination of clonazepam (C) lorazepam (L) and dexamethasone (D) to (L) and (D) to control vomiting induced by 50 mg/m CDDP containing chemotherapy for gynecological malignancies (p less than 0." | 7.68 | [Evaluation of antiemetic effect of clonazepam, metoclopramide, dexamethasone and diphenhydramine for prevention of cisplatin-induced vomiting]. ( Asano, H; Hatae, M; Hokanishi, H; Mitsuo, M; Nakamura, Y; Onishi, Y; Sakurai, K, 1990) |
| "Vomiting was not satisfactorily prevented by either treatment." | 6.67 | Betamethasone-dixyrazine versus betamethasone-metoclopramide as antiemetic treatment of cisplatin-doxorubicin-induced nausea in ovarian carcinoma patients. ( Hallén, C; Sorbe, B, 1991) |
| " It is concluded that there is a dose-response relationship for the antiemetic effect of metoclopramide." | 6.66 | High-dose versus low-dose metoclopramide in the prevention of cisplatin-induced emesis. A randomized crossover study in patients with ovarian carcinoma. ( Grande, T; Moxnes, A; Onsrud, M; Solesvik, O; Sollien, A, 1988) |
| "Metoclopramide was given at a dosage of 2 mg/kg (H) or 1 mg/kg (M), intravenously, 30 minutes before and 2." | 6.66 | [Randomized controlled study of high-dose metoclopramide (2 mg/kg x 4:H) vs moderate-dose metoclopramide (1 mg/kg x 4:M) in the prevention of CDDP-induced emesis]. ( Dozono, H; Ohmi, K, 1986) |
| "Metoclopramide (MCP) was given i." | 6.65 | Randomized open cross-over trial between metoclopramide (MCP) and dexamethazone (DXM) for the prevention of cisplatin-induced nausea and vomiting. ( Carlini, P; Cognetti, F; Conti, EM; Cortese, M; Pinnarò, P; Pollera, CF, 1984) |
| "and metoclopramide 0." | 5.29 | Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A, 1996) |
| "To evaluate the combined effect of granisetron and methylprednisolone against acute emesis induced by cytotoxic agents, we investigated the clinical response and the urinary excretion of 5-HIAA in 85 patients with ovarian cancer who received the same anticancer chemotherapeutic regimen in a prospective randomized trial." | 5.08 | Combination effect of granisetron and methylprednisolone for preventing emesis induced by cytotoxic agents. ( Cheng, X; Itamochi, H; Kigawa, J; Minagawa, Y; Okada, M; Terakawa, N, 1997) |
| "To improve the treatment of cisplatin-induced acute emesis and vomiting, the adjuvant effect of two different doses of metoclopramide and metoclopramide plus droperidol was compared to a defined standard antiemetic regiment." | 5.07 | Comparison of four antiemetic regimens for the treatment of cisplatin-induced vomiting. ( Hernádi, Z; Juhász, B; Lampé, L; Póka, R, 1993) |
| "To determine the severity of emesis caused by ultra-high-dose cisplatin-carboplatin chemotherapy and to compare the antiemetic efficacy of an ondansetron regimen and a metoclopramide regimen." | 5.07 | Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy. ( Fanning, J; Hilgers, RD, 1994) |
| " The syndrome was associated with metoclopramide antiemetic therapy given for post-operative nausea and vomiting." | 3.68 | Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy. ( Bakri, YN; Kawi, Z; Khan, R; Subhi, J, 1992) |
| "In prospective alternative crossover test, we confirmed significant superiority of a three-drug combination of clonazepam (C) lorazepam (L) and dexamethasone (D) to (L) and (D) to control vomiting induced by 50 mg/m CDDP containing chemotherapy for gynecological malignancies (p less than 0." | 3.68 | [Evaluation of antiemetic effect of clonazepam, metoclopramide, dexamethasone and diphenhydramine for prevention of cisplatin-induced vomiting]. ( Asano, H; Hatae, M; Hokanishi, H; Mitsuo, M; Nakamura, Y; Onishi, Y; Sakurai, K, 1990) |
| "Female patients with ovarian cancer are at high risk for emesis." | 2.67 | Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research. ( , 1994) |
| "Vomiting was not satisfactorily prevented by either treatment." | 2.67 | Betamethasone-dixyrazine versus betamethasone-metoclopramide as antiemetic treatment of cisplatin-doxorubicin-induced nausea in ovarian carcinoma patients. ( Hallén, C; Sorbe, B, 1991) |
| " It is concluded that there is a dose-response relationship for the antiemetic effect of metoclopramide." | 2.66 | High-dose versus low-dose metoclopramide in the prevention of cisplatin-induced emesis. A randomized crossover study in patients with ovarian carcinoma. ( Grande, T; Moxnes, A; Onsrud, M; Solesvik, O; Sollien, A, 1988) |
| "Metoclopramide was given at a dosage of 2 mg/kg (H) or 1 mg/kg (M), intravenously, 30 minutes before and 2." | 2.66 | [Randomized controlled study of high-dose metoclopramide (2 mg/kg x 4:H) vs moderate-dose metoclopramide (1 mg/kg x 4:M) in the prevention of CDDP-induced emesis]. ( Dozono, H; Ohmi, K, 1986) |
| "Metoclopramide (MCP) was given i." | 2.65 | Randomized open cross-over trial between metoclopramide (MCP) and dexamethazone (DXM) for the prevention of cisplatin-induced nausea and vomiting. ( Carlini, P; Cognetti, F; Conti, EM; Cortese, M; Pinnarò, P; Pollera, CF, 1984) |
| "and metoclopramide 0." | 1.29 | Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study. ( Cannata, G; Gebbia, N; Gebbia, V; Testa, A, 1996) |
| "Intestinal obstruction is a relatively common clinical problem in patients with advanced cancer, particularly those with colorectal and ovarian tumours." | 1.28 | Non-operative management of malignant intestinal obstruction. ( Elder, P; Isbister, WH; Symons, L, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (40.00) | 18.7374 |
| 1990's | 17 (56.67) | 18.2507 |
| 2000's | 1 (3.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cognetti, F | 1 |
| Pinnarò, P | 1 |
| Carlini, P | 1 |
| Conti, EM | 1 |
| Cortese, M | 1 |
| Pollera, CF | 1 |
| Bolis, PF | 1 |
| Guaschino, S | 1 |
| Paganelli, AM | 1 |
| Sampaolo, P | 1 |
| Misra, R | 1 |
| Agarwal, N | 1 |
| Póka, R | 1 |
| Hernádi, Z | 1 |
| Juhász, B | 1 |
| Lampé, L | 1 |
| Fanning, J | 1 |
| Hilgers, RD | 1 |
| Goddard, M | 1 |
| Hansen, O | 1 |
| Pfeiffer, P | 1 |
| Madsen, B | 1 |
| Andersen, I | 1 |
| Hansen, B | 1 |
| Mathiesen, B | 1 |
| Gebbia, V | 1 |
| Testa, A | 1 |
| Cannata, G | 1 |
| Gebbia, N | 1 |
| Kigawa, J | 1 |
| Minagawa, Y | 1 |
| Itamochi, H | 1 |
| Cheng, X | 1 |
| Okada, M | 1 |
| Terakawa, N | 1 |
| Sawaguchi, K | 1 |
| Yabushita, H | 1 |
| Tsukada, H | 1 |
| Yamada, H | 1 |
| Noguchi, M | 1 |
| Nakanishi, M | 1 |
| Morrow, GR | 1 |
| Hickok, JT | 1 |
| DuBeshter, B | 1 |
| Lipshultz, SE | 1 |
| Manusirivithaya, S | 1 |
| Chareoniam, V | 1 |
| Isariyodom, P | 1 |
| Sungsab, D | 1 |
| Fürst, CJ | 2 |
| Johansson, S | 2 |
| Fredrikson, M | 2 |
| Hursti, T | 2 |
| Steineck, G | 2 |
| Peterson, C | 2 |
| Bakri, YN | 1 |
| Khan, R | 1 |
| Subhi, J | 1 |
| Kawi, Z | 1 |
| Ochiai, K | 1 |
| Isonishi, S | 1 |
| Kimura, E | 1 |
| Yokoyama, S | 1 |
| Sasaki, H | 1 |
| Arihiro, T | 1 |
| Terashima, Y | 1 |
| Sorbe, B | 2 |
| Hallén, C | 2 |
| Isbister, WH | 1 |
| Elder, P | 1 |
| Symons, L | 1 |
| Hatae, M | 1 |
| Nakamura, Y | 1 |
| Mitsuo, M | 1 |
| Sakurai, K | 1 |
| Asano, H | 1 |
| Onishi, Y | 1 |
| Hokanishi, H | 1 |
| Chen, JT | 1 |
| Hirai, Y | 1 |
| Yagi, H | 1 |
| Katase, K | 1 |
| Shimizu, Y | 1 |
| Nakayama, K | 1 |
| Teshima, H | 1 |
| Hamada, T | 1 |
| Fujimoto, I | 1 |
| Yamuchi, K | 1 |
| Kobayashi, H | 1 |
| Onsrud, M | 1 |
| Moxnes, A | 1 |
| Sollien, A | 1 |
| Grande, T | 1 |
| Solesvik, O | 1 |
| Rosenblatt, E | 1 |
| Lev, LM | 1 |
| Robinson, E | 1 |
| Martin-Jimenez, M | 1 |
| Diaz-Rubio, E | 1 |
| Gonzalez Larriba, JL | 1 |
| Sangro, B | 1 |
| Breitbart, W | 1 |
| Dozono, H | 1 |
| Ohmi, K | 1 |
| Markman, M | 1 |
| Newman, DR | 1 |
| Hawkins, RS | 1 |
| Gez, E | 1 |
| Catane, R | 1 |
| Pfau, L | 1 |
| Biran, S | 1 |
18 trials available for metoclopramide and Ovarian Neoplasms
| Article | Year |
|---|---|
Randomized open cross-over trial between metoclopramide (MCP) and dexamethazone (DXM) for the prevention of cisplatin-induced nausea and vomiting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cl | 1984 |
Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Dexamethasone; Diphenhydramine; Drug Combinations; Drug T | 1994 |
Comparison of four antiemetic regimens for the treatment of cisplatin-induced vomiting.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Droperidol; Female; Humans; | 1993 |
Ondansetron and metoclopramide fail to prevent vomiting secondary to ultra-high-dose cisplatin-carboplatin chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dexamethasone; Diphenh | 1994 |
Sustained-release metoclopramide plus methylprednisolone versus placebo plus methylprednisolone as antiemetic prophylaxis during non-cisplatin chemotherapy. A randomized double-blind cross-over trial.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplas | 1996 |
Combination effect of granisetron and methylprednisolone for preventing emesis induced by cytotoxic agents.
Topics: Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Granisetron; Humans; Hydroxyi | 1997 |
[Clinical studies of oral antiemetic drugs on delayed emesis induced by cancer chemotherapy].
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Carboplatin; Cisplatin; Cross-Over Studies | 1999 |
Changes in clinical measures of autonomic nervous system function related to cancer chemotherapy-induced nausea.
Topics: Aged; Antiemetics; Antineoplastic Agents; Autonomic Nervous System; Blood Pressure; Carboplatin; Cis | 1999 |
Comparison of ondansetron-dexamethasone-lorazepam versus metoclopramide-dexamethasone-lorazepam in the control of cisplatin induced emesis.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Chi-Square Distribution; Cisplatin; Dexamethasone; | 2001 |
Effects of ondansetron on chemotherapy-induced acute and delayed emesis--a pilot study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Biperiden; Cisplatin; Dexa | 1991 |
Betamethasone-dixyrazine versus betamethasone-metoclopramide as antiemetic treatment of cisplatin-doxorubicin-induced nausea in ovarian carcinoma patients.
Topics: Activities of Daily Living; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethaso | 1991 |
Antiemetic treatment of chemotherapy-induced nausea in ovarian carcinoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antipsychotic Agents; Betamethasone; Cisplatin; Clin | 1989 |
[Effect of medical vagotomy on the CDDP induced nausea and vomiting evaluated by the chemotherapy-vomiting time (CV time)].
Topics: Acetaminophen; Adult; Cisplatin; Female; Humans; Metoclopramide; Middle Aged; Nausea; Ovarian Neopla | 1988 |
[The effect of metoclopramide, dexamethasone and antihistamine in the prevention of PAC chemotherapy-induced emesis].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; D | 1988 |
High-dose versus low-dose metoclopramide in the prevention of cisplatin-induced emesis. A randomized crossover study in patients with ovarian carcinoma.
Topics: Adult; Aged; Cisplatin; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Metoc | 1988 |
High-dose dexamethasone and high-dose metoclopramide versus high-dose dexamethasone and sulpiride in the management of cisplatin-induced emesis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dexamethasone; | 1988 |
Antiemetic combination for PAC (cisplatin-adriamycin-cyclophosphamide) chemotherapy-induced emesis in ovarian cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials | 1987 |
[Randomized controlled study of high-dose metoclopramide (2 mg/kg x 4:H) vs moderate-dose metoclopramide (1 mg/kg x 4:M) in the prevention of CDDP-induced emesis].
Topics: Aged; Cisplatin; Drug Administration Schedule; Female; Humans; Metoclopramide; Middle Aged; Nausea; | 1986 |
12 other studies available for metoclopramide and Ovarian Neoplasms
| Article | Year |
|---|---|
A comparison of droperidol and metoclopramide in the treatment of nausea and vomiting during cis-platinum polichemotherapy in ovarian carcinoma.
Topics: Antineoplastic Agents; Cisplatin; Droperidol; Drug Therapy, Combination; Female; Humans; Metoclopram | 1981 |
Effective control of cisplatin induced emesis by combination drug regimen.
Topics: Adult; Cisplatin; Dexamethasone; Drug Administration Schedule; Drug Combinations; Female; Follow-Up | 1994 |
The real costs of emesis.
Topics: Antiemetics; Carboplatin; Cisplatin; Drug Costs; Female; Humans; Metoclopramide; Ondansetron; Ovaria | 1993 |
Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Epirubicin; Female; Hu | 1996 |
Control of cisplatin induced emesis--a multidisciplinary intervention strategy.
Topics: Adult; Aged; Biperiden; Cisplatin; Female; Humans; Lorazepam; Metoclopramide; Middle Aged; Nausea; O | 1992 |
Neuroleptic malignant syndrome associated with metoclopramide antiemetic therapy.
Topics: Adenocarcinoma; Antiemetics; Female; Humans; Metoclopramide; Middle Aged; Nausea; Neuroleptic Malign | 1992 |
[Cyclic high dose CAP therapy by short-stay admission for ovarian malignancies--to increase total dose of CDDP and to improve quality of life of patients].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Dru | 1991 |
Non-operative management of malignant intestinal obstruction.
Topics: Adult; Aged; Colorectal Neoplasms; Drug Combinations; Female; Humans; Infusions, Intravenous; Intest | 1990 |
[Evaluation of antiemetic effect of clonazepam, metoclopramide, dexamethasone and diphenhydramine for prevention of cisplatin-induced vomiting].
Topics: Adult; Antiemetics; Cisplatin; Clonazepam; Dexamethasone; Diphenhydramine; Female; Humans; Metoclopr | 1990 |
Tardive dyskinesia associated with high-dose intravenous metoclopramide.
Topics: Adult; Dyskinesia, Drug-Induced; Female; Humans; Injections, Intravenous; Male; Metoclopramide; Midd | 1986 |
Parkinsonism following i.v. administration of high-dose metoclopramide used as an antiemetic agent during cancer chemotherapy.
Topics: Abdominal Neoplasms; Adenocarcinoma; Aged; Cisplatin; Female; Humans; Metoclopramide; Nausea; Ovaria | 1985 |
High-dose metoclopramide as an antiemetic in patients receiving cis-platinum-based combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Female; Humans; Male; Metoclopr | 1985 |